Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.

Corbus is advancing CRB-913, an oral peripherally restricted CB1 inverse agonist that showed rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study. The company expects to complete a 12-week Phase 1b dose-ranging study (n=240) in summer 2026.

Argus Mar 18 session

-6.02% close to close Open Argus

Details

News Market Reaction – CRBP

On Mar 18, the day this news came out, CRBP closed 6.02% below the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Key Figures

Phase 1a duration: 14 days Phase 1b duration: 12 weeks Phase 1b sample size: n=240 +2 more

Phase 1a duration

14 days

CRB-913 Phase 1a SAD/MAD obesity study

Phase 1b duration

12 weeks

Ongoing CRB-913 dose-ranging Phase 1b obesity study

Phase 1b sample size

n=240

CRB-913 Phase 1b dose-ranging obesity trial

Summit date

March 24, 2026

BMO 2026 Metabolic Health Summit panel participation

Panel time

12:45 pm Eastern Time

CRBP participation in Emerging Companies Panel at BMO summit

Historical Context

5 past events · Latest: Mar 09

5 events

1. Mar 09

   Earnings and pipeline

   24h Move

   +19.2%

   Q4 and 2025 results with CRB-701/CRB-913 data and cash runway update.

2. Feb 12

   Conference appearance

   24h Move

   +2.8%

   Announcement of CEO presentation and investor meetings at Oppenheimer conference.

3. Jan 05

   Conference presentation

   24h Move

   -0.5%

   J.P. Morgan Healthcare Conference corporate overview and one-on-one meetings.

4. Dec 11

   Phase 1a results

   24h Move

   -5.7%

   CRB-913 Phase 1a results showing weight loss and favorable safety profile in obesity.

5. Dec 10

   Data timing update

   24h Move

   -5.7%

   Notice of upcoming CRB-913 Phase 1a data release and conference call schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cb1 inverse agonist, phase 1a, dose-ranging

3 terms

cb1 inverse agonist medical

"CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment"

A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.

phase 1a medical

"favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

dose-ranging medical

"complete an ongoing Phase 1b dose-ranging 12-week study (n=240) in summer 2026."

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026.

Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long-term weight management solution for people struggling with chronic obesity. Corbus expects to complete an ongoing Phase 1b dose-ranging 12-week study (n=240) in summer 2026.

BMO 2026 Metabolic Health Summit
Emerging Companies Panel: What's Next in the Treatment of Metabolic Disease
Date: March 24, 2026
Time: 12:45 pm Eastern Time

The BMO 2026 Metabolic Health Summit will convene industry-leading BioPharma innovators, experts, and investors for a full day of thought leadership panels, fireside conversations with corporate management, and small-group or one-on-one meetings exploring the future of metabolic health innovation.

Participants interested in one-on-one meetings with Dr. Cohen at the summit should contact their BMO representative.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners.  Their use does not imply affiliation or endorsement by these companies.  

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Corbus (CRBP) present at the BMO 2026 Metabolic Health Summit?

Corbus CEO Yuval Cohen will participate on March 24, 2026 at 12:45 pm ET. According to Corbus, the appearance is part of the Emerging Companies Panel on metabolic disease treatments.

What is CRB-913 and what did Corbus (CRBP) report about it?

CRB-913 is an oral, peripherally restricted CB1 inverse agonist for obesity treatment. According to Corbus, it produced potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study.

When does Corbus (CRBP) expect to complete the Phase 1b study for CRB-913?

Corbus expects to complete the ongoing 12-week Phase 1b dose-ranging study (n=240) in summer 2026. According to Corbus, this study will inform dosing for later trials.

How can investors arrange one-on-one meetings with Corbus (CRBP) at the summit?

Investors should contact their BMO representative to request one-on-one meetings with Dr. Cohen. According to Corbus, BMO will coordinate small-group and individual meeting schedules at the summit.

What topics will Corbus (CRBP) likely discuss at the BMO 2026 Metabolic Health Summit?

Corbus will discuss developments in metabolic disease treatment and CRB-913 clinical progress. According to Corbus, the panel focuses on what's next in treating metabolic disease and innovation trends.